Avalo Therapeutics Inc. buy melinda
Summary
This prediction ended on 01.11.18 with a price of €47.08. The BUY prediction by melinda finished with a performance of 10.13%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Avalo Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | 1.743% | 1.903% | 18.038% | 16.248% |
iShares Nasdaq 100 | -2.088% | -0.640% | 25.594% | 34.551% |
iShares Nikkei 225® | 1.306% | 4.161% | 16.556% | 10.486% |
iShares S&P 500 | -0.093% | 0.169% | 24.312% | 36.773% |
Comments by melinda for this prediction
In the thread Avalo Therapeutics Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Métier
Operates as a clinical stage biopharmaceutical company
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development.
It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders.
It products include CERC-301, CERC-501, CERC-611, and CERC-406.
The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
Nombre d'employés : 38 personnes.
Stopped prediction by melinda for Avalo Therapeutics Inc.
Avalo Therapeutics Inc.
08.09.20
04.11.21
05.11.21
Avalo Therapeutics Inc.
25.08.20
08.09.20
08.09.20
Avalo Therapeutics Inc.
27.02.19
30.10.19
30.10.19
Avalo Therapeutics Inc.
02.12.18
14.01.19
14.01.19
Avalo Therapeutics Inc.
27.02.18
28.08.18
28.08.18
Avalo Therapeutics Inc.
13.01.18
05.02.18
05.02.18
Avalo Therapeutics Inc.
29.11.17
19.12.17
19.12.17
Avalo Therapeutics Inc.
29.11.17
19.12.17
19.12.17
Avalo Therapeutics Inc.
28.01.17
28.07.17
28.07.17